2-叔丁基-1-甲基吡咯并[2,3-b]吡啶 | 113975-30-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 2-叔丁基-1-甲基吡咯并[2,3-b]吡啶
• 英文名称: 2-tert-butyl-1-methylpyrrolo<2,3-b>pyridine
• 英文别名: 2-(tert-butyl)-1-methyl-1H-pyrrolo[2,3-b]pyridine；2-tert-butyl-1-methylpyrrolo[2,3-b]pyridine
• CAS: 113975-30-7
• 化学式: C₁₂H₁₆N₂
• mdl: MFCD02083385
• 分子量: 188.272
• InChiKey: INRHCCQAZBZFKW-UHFFFAOYSA-N

物化性质

• 沸点：
  300.2±22.0 °C(Predicted)
• 密度：
  1.01±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  methyl(3-iodopyridin-2-yl)amine 在 盐酸 、 potassium tert-butylate 作用下， 反应 6.08h， 生成 2-叔丁基-1-甲基吡咯并[2,3-b]吡啶
  参考文献：
  名称：

  Metalation/SRN1 coupling in heterocyclic synthesis. A convenient methodology for ring functionalization

  摘要：

  DOI：

  10.1021/jo00247a016

文献信息

• QUINOLONE COMPOUND
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20140179675A1

  公开（公告）日：2014-06-26

  The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R 1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R 2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R 3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile -associated diarrhea.

  本发明提供了一种由式(I)表示的化合物 其中X是氢原子或氟原子；R是氢原子或烷基；R 1 是(1)环丙基，可选地取代1至3个卤素原子，或(2)苯基，可选地取代1至3个卤素原子；R 2 是烷基，烷氧基，卤代烷氧基，卤素原子，氰基等；R 3 是7-氧代-7,8-二氢-1,8-萘啉基，3-吡啶基等，或其盐。本发明的化合物对 艰难梭菌 具有优异的抗菌活性，并可用于预防或治疗肠道感染，如 艰难梭菌 相关性腹泻。
• Pyrazolo pyrimidines useful as aurora kinase inhibitors
  申请人：Oslob D. Johan

  公开号：US20070027166A1

  公开（公告）日：2007-02-01

  The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: wherein one of is a double bond, as valency permits; and R 2 , R 4 , X 1A , X 2A , X 1B , X 2B , L 1 , L 2 , Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.

  本发明提供具有以下结构的化合物：其中A-B一起代表以下结构之一：其中之一是双键，根据价性而定；而R2、R4、X1A、X2A、X1B、X2B、L1、L2、Y和Z如此处所定义，以及其制药组合物，如此处总体描述和所述的亚类，这些化合物可用作蛋白激酶（例如Aurora）的抑制剂，因此可用于例如治疗由Aurora介导的疾病。
• THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS
  申请人：Lew Willard

  公开号：US20100179123A1

  公开（公告）日：2010-07-15

  The present invention provides compounds having the formula: wherein R 1 , R 2 , X 1 , X 2 , L 1 , L 2 , Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.

  本发明提供具有以下式子的化合物：其中R1，R2，X1，X2，L1，L2，Y和Z在本类和子类中定义，并描述了其药物组成物，如本类和子类中一般所述。这些化合物可用作蛋白激酶（例如，极光激酶）的抑制剂，因此可用于治疗极光激酶介导的疾病。
• ESTEL, L.;MARSAIS, F.;QUEGUINER, G., J. ORG. CHEM., 53,(1988) N 12, 2740-2744
  作者：ESTEL, L.、MARSAIS, F.、QUEGUINER, G.

  DOI：——

  日期：——
• ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSIS COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND
  申请人：SAMSUNG ELECTRONICS CO., LTD.

  公开号：US20170047532A1

  公开（公告）日：2017-02-16

  An organometallic compound represented by Formula 1: M(L 1 )(L 2 )   Formula 1 wherein in Formula 1, M, L 1 , and L 3 are the same as described in the specification.